Loading clinical trials...
Loading clinical trials...
Combined Effects of Transcutaneous Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Upper Extremity Function, Cognition and Quality of Life in Individual With Chronic Stroke
Stroke is a leading cause of death and disability worldwide, resulting in significant physical and cognitive impairments. Arm weakness is most common after stroke and its treatment is recognized as an area of considerable need. The functional limitations and disabilities experienced by stroke survivors, particularly in the upper limb have a profound impact on their quality of life. Current treatment for arm weakness typically comprises intensive, task-specific and repetitive rehabilitative interventions. Transcutaneous auricular vagus nerve stimulation (tVNS) is a novel noninvasive treatment for stroke that directly stimulates the peripheral auricular branch of the vagus nerve. This study determines the effects of Vagus Nerve Stimulation and Modified Constraint Induced Movement Therapy on Motor Function, Cognition, and Quality of life in chronic stroke patients. This randomized clinical trial will be conducted at IIMCT Railway General Hospital and Al-firdous physiotherapy clinic over a duration of six months. The sample size will consist of 50 participants. Participants which meet the inclusion criteria will be taken through non-probability convenience sampling technique, which will further be randomized through online randomization tool. 25 Participants will be assigned to Group A receiving tVNS and mCIMT with routine physical therapy and 25 to Group B receiving mCIMT with routine physical therapy . Data will be collected using various assessment tools, including Fugl-Meyer Assessment-UE (FM-UE), and Nine-hole peg test (NHPT) to assess Motor function. Stroke Impact Scale (SIS) to assess QOL, Montreal cognitive assessment (MoCA) to assess cognition, and Modified Ashworth scale to assess spasticity. All participants will receive intervention 3 days a week on alternative days for 8 weeks. Pre-intervention assessments will be conducted for both groups. The effects of the interventions will be measured at pre-treatment, 4th week, and post-intervention. Data analysis will be performed by using SPSS 26 software. Key words: Modified Constraint Induced movement Therapy, Motor function, Rehabilitation, Stroke, Transcutaneous Vagus nerve stimulation, Upper extremity.
Stroke is the third leading cause of death and the leading cause of adult disability. Patients with stroke suffer from neuromuscular disabilities, including impairments in motor control. Stroke survivors with hemiplegia exhibit more upper-limb (UL) than lower-limb (LL) disability. Dysfunction from upper extremity hemi paresis impairs performance of many daily activities such as dressing, bathing, self-care and writing, thus reducing functional independence. Only 5% of adults regain full arm function after stroke, and 20% regain no functional use. Restoration of full function to the stroke affected upper extremity is a major problem in rehabilitation. Hence alternative strategies are needed to reduce the long-term disabilities and functional impairment resulting from upper extremity hemi paresis. The severity of the neurological deficits and early patterns of improvement are the two best predictors of recovery from impairments. Patients are generally thought to experience less UL motor recovery than LL motor recovery; however, this clinical belief is typically based on disability assessments rather than tests of specific motor deficits of UL and LL. Since UL function needs finer motor control than LL function, this might explain the common scenario of less variation between impairment and disability. There are several promising treatment options available for upper-limb stroke rehabilitation, such as cross education, constraint-induced movement therapy, virtual reality therapy, functional electrical stimulation, robotic therapy, anodal transcranial direct current stimulation, and motor imagery. Unfortunately, VNS necessitates a costly, invasive surgical procedure. In the last years, transcutaneous VNS (ta-VNS) has been proposed as a noninvasive and patient friendly method to stimulate the vagus nerve, through the skin, by delivering weak electric current to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. Such stimulation activates the auricular branch of the vagus nerve and, via this pathway, the nuclei of the nerve located in the brainstem, enhancing brain GABA and Noradrenaline levels, which plays a pivotal role in brain plasticity. These connections regulate the release of neuromodulators, including acetylcholine, norepinephrine, serotonin, and brain-derived neurotrophic factors, which promote cortical plasticity. The rationale for this study lies in its potential to uncover synergistic benefits from combining these two therapies, ultimately aiming to enhance functional recovery and cognitive engagement among chronic stroke survivors, thereby improving their daily lives and reintegration into society. The exploration of effective rehabilitation strategies is crucial, as traditional therapies frequently provide limited benefits for chronic stroke patients, particularly concerning upper extremity function. This research investigates the combined effects of ta-VNS and Modified CIMT on these patients, aiming to enhance motor recovery and cognitive engagement. The findings may inform future therapeutic approaches and offer hope for improved independence and well-being among individuals affected by chronic stroke.
Age
50 - 75 years
Sex
ALL
Healthy Volunteers
No
Al- firdous physiotherapy clinic
Rawalpindi, Punjab Province, Pakistan
IIMCT- Railway General Hospital
Rawalpindi, Punjab Province, Pakistan
Start Date
November 25, 2025
Primary Completion Date
May 5, 2026
Completion Date
May 5, 2026
Last Updated
December 9, 2025
50
ESTIMATED participants
Transcutaneous Vagus Nerve Stimulation
DEVICE
Modified Constraint Induced Movement Therapy with Routine Physical Therapy
OTHER
Lead Sponsor
Riphah International University
NCT07371455
NCT05093673
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06258538